Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPACE-PAIN
2024-516936-93-02Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) and chronic neuropathic pain comparing Psilocybin 25 mg with Psilocybin 1 mg (active placebo / low dose) (2 arms). Primary endpoints: Patient recruitment and retention rates, and completeness of outcome data, Patient expectancy (SETS) and 5 more. Planned start Dec 2024; status: authorised.
02
Drugs
psilocybin
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)chronic neuropathic pain
Beyond the preview
Go deeper on 2024-516936-93-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516936-93-02.